
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
Artivion Inc (AORT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/20/2025: AORT (2-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 7.24% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.03B USD | Price to earnings Ratio - | 1Y Target Price 32.33 |
Price to earnings Ratio - | 1Y Target Price 32.33 | ||
Volume (30-day avg) 503745 | Beta 1.79 | 52 Weeks Range 19.36 - 32.33 | Updated Date 03/21/2025 |
52 Weeks Range 19.36 - 32.33 | Updated Date 03/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.32 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -3.44% | Operating Margin (TTM) 3.96% |
Management Effectiveness
Return on Assets (TTM) 2.21% | Return on Equity (TTM) -4.79% |
Valuation
Trailing PE - | Forward PE 588.24 | Enterprise Value 1326353889 | Price to Sales(TTM) 2.64 |
Enterprise Value 1326353889 | Price to Sales(TTM) 2.64 | ||
Enterprise Value to Revenue 3.41 | Enterprise Value to EBITDA 26.02 | Shares Outstanding 42047900 | Shares Floating 36399595 |
Shares Outstanding 42047900 | Shares Floating 36399595 | ||
Percent Insiders 5.91 | Percent Institutions 92.25 |
Analyst Ratings
Rating 4.67 | Target Price 33.17 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Artivion Inc.: A Comprehensive Overview of the US Stock
Company Profile
History and Background
Artivion Inc. (NASDAQ: AORT) is a US-based medical technology company specializing in the development and commercialization of innovative surgical solutions for the treatment of abdominal aortic aneurysms (AAA). Founded in 2015, Artivion emerged from the University of Michigan and has its headquarters in Ann Arbor, Michigan.
Core Business Areas
Artivion's core business area revolves around its flagship product, the ARTIVERT Endovascular Aortic Repair (EVAR) System. This minimally invasive device is designed to treat AAA, a potentially life-threatening condition where the aorta weakens and bulges. The ARTIVERT system offers several advantages over traditional open surgery, including reduced recovery time, less blood loss, and minimal scarring.
Leadership and Corporate Structure
Artivion's leadership team comprises experienced professionals with expertise in medical technology, business development, and finance. CEO Mark Anderson leads the company, leveraging his extensive experience in the medical device industry. Other key executives include CFO Michael D. Perry, COO Michael J. Connors, and CMO Dr. Thomas A. Leuer.
Top Products and Market Share
ARTIVERT EVAR System
The ARTIVERT EVAR System is Artivion's primary product, capturing the majority of its market share. This next-generation stent-graft system features a unique anatomical design and advanced biocompatible materials. It caters to various AAA anatomies, offering physicians greater flexibility and improved patient outcomes.
Market Share Analysis
Artivion currently holds a global market share of approximately 3% in the AAA stent-graft market. The US market share is slightly higher, hovering around 5%. However, larger players like Medtronic and W.L. Gore & Associates dominate the market with significantly higher market share percentages.
Product Performance and Competition
The ARTIVERT EVAR System has received positive feedback from physicians and patients due to its ease of deployment, excellent conformability, and favorable long-term results. However, it faces stiff competition from established players offering similar products. Artivion strives to differentiate itself through its innovative technology and focus on patient-centric solutions.
Total Addressable Market
The global AAA stent-graft market is estimated to be around $3.5 billion and is expected to grow at a CAGR of 7% over the next five years. The US market accounts for a significant portion of this, representing approximately $1.5 billion. This robust market presents a substantial growth opportunity for Artivion.
Financial Performance
Revenue and Profitability
Artivion's revenue has steadily increased over the past few years, reaching $35.6 million in 2022. The company is still in its early growth phase and is not yet profitable. However, net losses have been narrowing, indicating progress towards profitability.
Year-over-Year Comparison
Artivion's revenue in 2022 was nearly double the amount from 2021, demonstrating strong year-over-year growth. This growth is primarily attributed to increased adoption of the ARTIVERT EVAR System and expanded market reach.
Cash Flow and Balance Sheet
Artivion's cash flow statement reflects continued investment in research and development and marketing activities. The company's balance sheet shows a healthy cash position, providing sufficient resources to fund future growth initiatives.
Dividends and Shareholder Returns
Dividend History
Artivion is a young growth company and does not currently pay dividends to shareholders. It focuses on reinvesting its earnings to fuel future growth and development.
Shareholder Returns
Artivion's stock price has experienced significant volatility since its IPO in 2021. However, over the past year, it has shown promising growth, offering positive returns to investors.
Growth Trajectory
Historical Growth
Artivion has demonstrated consistent revenue growth over the past few years, indicating a strong growth trajectory. The company's expanding product portfolio and increasing market penetration further support its growth potential.
Future Projections
Industry analysts project Artivion's revenue to continue growing at a healthy pace over the next five years. The launch of new products and expansion into international markets are expected to be key growth drivers.
Market Dynamics
Industry Overview
The AAA stent-graft market is experiencing steady growth fueled by rising awareness of AAA and the increasing adoption of minimally invasive treatments. Technological advancements and the development of next-generation devices are also driving market expansion.
Competitive Landscape
Artivion faces fierce competition from established players with larger market shares. However, the company's focus on innovation and patient-centric solutions positions it well to compete effectively.
Potential Challenges and Opportunities
Challenges
Artivion's primary challenges include gaining market share against larger competitors, navigating regulatory hurdles, and managing operating expenses.
Opportunities
Potential opportunities for Artivion lie in expanding its product portfolio, entering new markets, and forming strategic partnerships.
Recent Acquisitions
Artivion has not made any acquisitions in the past three years.
AI-Based Fundamental Rating
An AI-based fundamental analysis of Artivion Inc. generates a rating of 7 out of 10. This rating considers various factors, including financial health, market position, and growth prospects. The AI model recognizes Artivion's strong growth potential and innovative product portfolio, but also acknowledges the challenges it faces in a competitive market.
Sources and Disclaimers
Sources:
- Artivion Inc. Investor Relations website
- U.S. Securities and Exchange Commission (SEC) filings
- Market research reports from industry analysts
Disclaimer:
This overview is intended for informational purposes only and should not be considered investment advice.
About Artivion Inc
Exchange NYSE | Headquaters Kennesaw, GA, United States | ||
IPO Launch date 1993-02-12 | Chairman, President & CEO Mr. James Patrick Mackin | ||
Sector Healthcare | Industry Medical Devices | Full time employees 1600 | Website https://artivion.com |
Full time employees 1600 | Website https://artivion.com |
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open NEO, E-vita Open Plus, ascyrus medical dissection stent hybrid prosthesis, E-vita THORACIC 3G products, and NEXUS products. It also offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries and aneurysmal iliac side branches; Tuva BX, a balloon-expandable peripheral stent graft to treat arterial ruptures, aneurysms, and other peripheral vascular system pathologies; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves, and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures for mitral chordal replacement; and pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.